Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Pathol. 2008 Mar;172(3):786-98. doi: 10.2353/ajpath.2008.070904. Epub 2008 Feb 7.

Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

Author information

1
Experimental Genetics Group, Department Human Genetics, Katholieke Universiteit Leuven-Campus Gasthuisberg ON1-06.602, B-3000 Leuven, Belgium.

Abstract

The hypothesis that amyloid pathology precedes and induces the tau pathology of Alzheimer's disease is experimentally supported here through the identification of GSK-3 isozymes as a major link in the signaling pathway from amyloid to tau pathology. This study compares two novel bigenic mouse models: APP-V717I x Tau-P301L mice with combined amyloid and tau pathology and GSK-3beta x Tau-P301L mice with tauopathy only. Extensive and remarkable parallels were observed between these strains including 1) aggravation of tauopathy with highly fibrillar tangles in the hippocampus and cortex; 2) prolonged survival correlated to alleviated brainstem tauopathy; 3) development of severe cognitive and behavioral defects in young adults before the onset of amyloid deposition or tauopathy; and 4) presence of pathological phospho-epitopes of tau, including the characteristic GSK-3beta motif at S396/S404. Both GSK-3 isozymes were activated in the brain of parental APP-V717I amyloid mice, even at a young age when cognitive and behavioral defects are evident but before amyloid deposition. The data indicate that amyloid induces tauopathy through activation of GSK-3 and suggest a role for the kinase in maintaining the functional integrity of adult neurons.

PMID:
18258852
PMCID:
PMC2258274
DOI:
10.2353/ajpath.2008.070904
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center